493 results on '"McLean, Huong Q"'
Search Results
52. Use of Influenza Antiviral Medications Among Outpatients at High Risk for Influenza-Associated Complications During the 2013–2014 Influenza Season
53. Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type
54. Early Estimates of Seasonal Influenza Vaccine Effectiveness — United States, January 2015
55. Impact of Repeated Vaccination on Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons
56. Vaccine-associated attenuation of subjective severity among outpatients with influenza
57. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness
58. Use of Influenza Antiviral Agents by Ambulatory Care Clinicians During the 2012–2013 Influenza Season
59. Interim Estimates of 2013–14 Seasonal Influenza Vaccine Effectiveness — United States, February 2014
60. Measles
61. Urban and rural healthcare providers' perspectives on HPV vaccination in Minnesota.
62. Influenza Vaccine Effectiveness Against Influenza A(H3N2)-Related Illness in the United States During the 2021–2022 Influenza Season.
63. Influenza Vaccine Effectiveness Among Children: 2011-2020.
64. Determinants of human papillomavirus vaccine attitudes: an interview of Wisconsin parents
65. SARS-CoV-2 Virus Dynamics in Recently Infected People—Data From a Household Transmission Study
66. Effectiveness of COVID-19 mRNA vaccine booster dose relative to primary series during a period of Omicron circulation
67. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013 : Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP)
68. Additional file 1 of Human papillomavirus vaccine beliefs and practice characteristics in rural and urban adolescent care providers
69. Implications of Shortened Quarantine Among Household Contacts of Index Patients with Confirmed SARS-CoV-2 Infection--Tennessee and Wisconsin, April-September 2020
70. SARS-CoV-2 virus dynamics in recently infected people - data from a household transmission study
71. Household Transmission and Clinical Features of SARS-CoV-2 Infections
72. mRNA COVID‐19 vaccine effectiveness against SARS‐CoV‐2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021
73. Vaccine effectiveness against COVID‐19 among symptomatic persons aged ≥12 years with reported contact with COVID‐19 cases, February–September 2021
74. Vaccine Effectiveness against COVID-19 among Symptomatic Persons Aged ≥12 Years with Reported Contact with COVID-19 Cases, February – September 2021
75. Seroprevalence of Measles, Mumps, Rubella and Varicella Antibodies in the United States Population, 2009–2010
76. mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020-December 2021
77. Serologic response to sequential vaccination with enhanced influenza vaccines: Open label randomized trial among adults aged 65–74 years
78. Effectiveness of two and three mRNA COVID‐19 vaccine doses against Omicron‐ and Delta‐Related outpatient illness among adults, October 2021–February 2022.
79. Publishing interim early or mid-season influenza vaccine effectiveness – US Flu VE Network
80. Messenger RNA Vaccine Effectiveness Against Coronavirus Disease 2019 Among Symptomatic Outpatients Aged ≥16 Years in the United States, February–May 2021
81. Household Transmission and Clinical Features of SARS-CoV-2 Infections by Age in 2 US Communities
82. mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged ≥16 Years in the United States, February – May 2021
83. Temporal Trends in Undervaccination: A Population-Based Cohort Study
84. Risk of symptomatic severe acute respiratory syndrome coronavirus 2 infection not associated with influenza vaccination in the 2019–2020 season
85. Sample size considerations for mid-season estimates from a large influenza vaccine effectiveness network in the United States
86. Influenza vaccination coverage among persons seeking outpatient medical care for acute respiratory illness in five states in the United States, 2011–2012 through 2018–2019
87. Systematic Testing for Influenza and Coronavirus Disease 2019 Among Patients With Respiratory Illness
88. Effect of Antigenic Drift on Influenza Vaccine Effectiveness in the United States—2019–2020
89. Impact of Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in Children
90. Role of Age in the Spread of Influenza, 2011–2019: Data From the US Influenza Vaccine Effectiveness Network.
91. Relative effectiveness of high dose versus standard dose influenza vaccines in older adult outpatients over four seasons, 2015–16 to 2018–19
92. Hospital Discharge Data Underascertain Enteric Bacterial Infections Among Children
93. Adverse Events Among Young Adults Following a Third Dose of Measles-Mumps-Rubella Vaccine
94. Earliest infections predict the age distribution of seasonal influenza A cases
95. Patterns of Influenza Vaccination and Vaccine Effectiveness Among Young US Children Who Receive Outpatient Care for Acute Respiratory Tract Illness
96. Effects of Prior Season Vaccination on Current Season Vaccine Effectiveness in the United States Flu Vaccine Effectiveness Network, 2012–2013 Through 2017–2018
97. Reducing Antibiotic Use in Ambulatory Care Through Influenza Vaccination
98. Influenza Vaccine Effectiveness in Inpatient and Outpatient Settings in the United States, 2015–2018
99. Author response: Earliest infections predict the age distribution of seasonal influenza A cases
100. Clinical trial to assess immunogenicity of high-dose, adjuvanted, and recombinant influenza vaccines against cell-grown A(H3N2) viruses in adults 65 to 74 years, 2017–2018
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.